CD229

Our CD229 CAR-T products and services are aimed at helping researchers and biopharmaceutical companies accelerate their development of innovative cancer immunotherapies. Please find our product offering available below.

Background

Cluster of differentiation 229 (CD229), also known as the lymphocyte cell-surface molecule Ly-9 or SLAMF3, is type I transmembrane glycoproteins. CD229 belongs to the signaling lymphocytic activation molecule family (SLAMF) of immune receptors, which play a crucial role in immune cell activation and development. CD229 is primarily found on the surface of lymphocytes, particularly T and B cells. It acts as a cell adhesion molecule, allowing cells to interact and adhere to each other during immune responses. It is also involved in the development and function of immune cells, including the regulation of T-cell activation and tolerance. Abnormal expression or dysregulation of CD229 has been associated with certain diseases and conditions, including cancer and autoimmune disorders. It has been suggested that CD229 may serve as a potential therapeutic target or prognostic marker in cancers such as acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and B-cell non-Hodgkin lymphomas.

Associated Disease

• Acute lymphoblastic leukemia (ALL)
• Chronic lymphocytic leukemia (CLL)

Anti-CD229 CAR-T Services

Creative Biolabs provides the one-stop solution to meet all your CD229 CAR-T research needs. Our team design and optimize CAR constructs tailored to your specific research requirements. Our scientists are experienced in CAR-T in vitro and in vivo studies from optimal design to execution. In addition, our dedicated technical support team is available to assist with any questions or concerns you may have during the development of your CAR-T therapy research.

Anti-CD229 CAR-T In Vitro Assays

• Anti-CD229 CAR-T Expression Test

Creative Biolabs offers a comprehensive assessment service to test the level of CD229 CAR. For example, flow cytometry is a widely used method to analyze CAR expression on the surface of cells.

Fig.1 Surface expression of CD229-CAR as evaluated by flow cytometry.¹

Anti-CD229 CAR-T Proliferation Test

In vitro CAR-T cell proliferation involves culturing and stimulating CAR-T cells with specific growth factors or antigens to promote their expansion. Our experts provide several tests to evaluate the proliferation capacity of CAR-T cells in vitro and monitor their growth over time, providing valuable insights into their therapeutic potential.

Fig.2 Determination of CD229-CAR proliferation using flow cytometry.¹

• Anti-CD229 CAR-T Cytokine Release Test

Creative Biolabs provides cytokine release test services using various technologies that allow for the determination of the level of a single cytokine or the simultaneous measurement of multiple cytokines in a single sample.

Fig.3 The cytokine levels in the supernatant when anti-CD229 CAR-T cells co-cultured with CD229-positive U-266 cell line.¹

• Anti-CD229 CAR-T In Vitro Cytotoxicity Assay

Cytotoxicity assays can provide valuable information for the effectiveness of CAR-T cells and for determining the appropriate CAR-T cell dosage for clinical applications. We perform several cytotoxicity assays to assess the effectiveness of anti-CD229 CAR-T cells in killing cancer cells.

Fig.4 The cytotoxicity of anti-CD229 CAR-T cells against tumor cells.¹

• Anti-CD229 CAR-T In Vivo Assays

Our comprehensive services include the evaluation of the anti-tumor efficacy of CD229 CAR-T therapies in mice models. We have a team of experienced researchers who can assist you in designing and conducting the experiments. We can work with both subcutaneous and orthotopic tumor models depending on your specific requirements. The tumor growth and regression are monitored over time to evaluate the efficacy of CAR-T therapy.

Fig.5 Anti-tumor activity of anti-CD229 CAR-T cells in vivo.¹

Reference

1. Radhakrishnan, Sabarinath V., et al. "CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide." Nature communications 11.1 (2020): 798.